On the other thread it was posted that figures for Ecclock sales...

On the other thread it was posted that figures for Ecclock sales in Japan have been released (I think to investors and analysts only at this stage) and it is being interpreted by analysts as something like this:

"Impact - These figures provide insight into the potential future sales of Sofpironium Bromide in the United States, underscoring the considerable market opportunity at hand. Based on our analysis, we estimate Kaken sold ~72,000 prescriptions in 2Q, or +287,000 prescriptions on an annualised basis (Figure 4).More so, when applied to our estimate of US pricing (US$540/month; net), this annualised 2Q prescription figure implies ~A$239 million of annual revenues in the United States (Figure 5).Additionally, this is based on Japanese prescription volumes, the United States has a population nearly 3x larger than Japan – which would suggest even larger potential prescription volumes and sales are possible. "